Anti-CD38 autoantibodies in type? Diabetes

Diabetes/Metabolism Research and Reviews

Volumn 22, Issue 4, 2006, Pages 284-294

  Mallone, Roberto ^a   Perin, Paolo Cavallo ^b  

^a INSERM   (France)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Beta cell autoimmunity; Insulin resistance; Type 1 diabetes; Type 2 diabetes

Indexed keywords

AUTOANTIBODY; CALCIUM ION; CD38 ANTIGEN; GLUCOSE; INSULIN;

ANTIBODY TITER; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CALCIUM MOBILIZATION; EPIDEMIOLOGICAL DATA; GLUCOSE HOMEOSTASIS; HUMAN; IMMUNOPATHOGENESIS; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; ONSET AGE; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; REVIEW;

ANTIGENS, CD38; AUTOANTIBODIES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN RESISTANCE; ISLETS OF LANGERHANS; MODELS, IMMUNOLOGICAL;

EID: 33746092912     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.626     Document Type: Review

References (83)

1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2004; 27(Suppl. 1): S5-S10.
2. Atkinson MA, Maclaren NK. The pathogenesis of insulin-dependent diabetes mellitus. N Engl J Med 1994; 331: 1428-1436.
3. DeFronzo RA, Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 1988; 37: 667-687.
4. Rosenbloom AL. Obesity, insulin resistance, beta-cell autoimmunity, and the changing clinical epidemiology of childhood diabetes. Diabetes Care 2003; 26: 2954-2956.
5. Witkin TJ. The accelerator hypothesis: weight gain as the missing link between Type I and Type II diabetes. Diabetologia 2001; 44: 914-922.
6. The DCCT Research Group. Effects of age, duration and treatment of insulin-dependent diabetes mellitus on residual beta-cell function: observations during eligibility testing for the Diabetes Control and Complications Trial (DCCT). J Clin Endocrinol Metab 1987; 65: 30-36.
7. Turner R, Stratton I, Horton V, et al. UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK Prospective Diabetes Study Group. Lancet 1997; 350: 1288-1293.
8. Leslie RD, Delli CM. Age-dependent influences on the origins of autoimmune diabetes: evidence and implications. Diabetes 2004; 53: 3033-3040.
9. Greenbaum CJ. Insulin resistance in type 1 diabetes. Diabetes Metab Res Rev 2002; 18: 192-200.
10. Fourlanos S, Narendran P, Byrnes GB, et al. insulin resistance is a risk factor for progression to type 1 diabetes. Diabetologia 2004; 47: 1661-1667.
11. Schober E, Schernthaner G, Frisch H, et al. Beta-cell function recovery is not the only factor responsible for remission in type I diabetics: evaluation of C-peptide secretion in diabetic children after first metabolic recompensation and at partial remission phase. J Endocrinol Invest 1984; 7: 507-512.
12. Yki-Jarvinen H, Koivisto VA. Natural course of insulin resistance in type I diabetes. N Engl J Med 1986; 315: 224-230.
13. Yki-Jarvinen H, Koivisto VA. Insulin sensitivity in newly diagnosed type 1 diabetics after ketoacidosis and after three months of insulin therapy. J Clin Endocrinol Metab 1984; 59: 371-378.
14. Hramiak IM, Dupre J, Finegood DT. Determinants of clinical remission in recent-onset IDDM. Diabetes Care 1993; 16: 125-132.
15. Yki-Jarvinen H. Glucose toxicity. Endocr Rev 1992; 13: 415-431.
16. Gottlieb MS. Diabetes in offspring and siblings of juvenile- and maturity-onset-type diabetics. J Chronic Dis 1980; 33: 331-339.
17. Dahlquist G, Blom L, Tuvemo T, et al. The Swedish childhood diabetes study-results from a nine year case register and a one year case-referent study indicating that type 1 (insulin-dependent) diabetes mellitus is associated with both type 2 (non-insulin-dependent) diabetes mellitus and autoimmune disorders. Diabetologia 1989; 32: 2-6.
18. Rich SS, Panter SS, Goetz FC, et al. Shared genetic susceptibility of type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetes mellitus: contributions of HLA and haptoglobin. Diabetologia 1991; 34: 350-355.
19. Li H, Lindholm E, Almgren P, et al. Possible human leukocyte antigen-mediated genetic interaction between type 1 and type 2 Diabetes. J Clin Endocrinol Metab 2001; 86: 574-582.
20. Pickup JC, Mattock MB, Chusney GD, et al. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 1997; 40: 1286-1292.
21. Feingold KR, Grunfeld C. Role of cytokines in inducing hyperlipidemia. Diabetes 1992; 41(Suppl. 2): 97-101.
22. Grunfeld C, Zhao C, Fuller J, et al. Endotoxin and cytokines induce expression of leptin, the ob gene product, in hamsters. J Clin Invest 1996; 97: 2152-2157.
23. Bornstein SR. Is leptin a stress related peptide? Nat Med 1997; 3: 937.
24. Bonifacio E, Mollenhauer U, Buuck D, et al. C-reactive protein concentration is not related to islet autoimmunity status in offspring of parents with type 1 diabetes. Clin Immunol 2005; 115: 173-177.
25. Basu S, Larsson A, Vessby J, et al. Type 1 diabetes is associated with increased cyclooxygenase- and cytokine-mediated inflammation. Diabetes Care 2005; 28: 1371-1375.
26. Waris ME, Koskinen JO, Simell O, et al. Onset of beta-cell autoimmunity is not associated with elevated concentration of C-reactive protein in children at genetic risk for Type 1 diabetes. Diabet Med 2005; 22: 1123-1124.
27. Yngen M, Ostenson CG, Hu H, et al. Enhanced P-selectin expression and increased soluble CD40 Ligand in patients with Type 1 diabetes mellitus and microangiopathy: evidence for platelet hyperactivity and chronic inflammation. Diabetologia 2004; 47: 537-540.
28. Schram MT, Chaturvedi N, Schalkwijk CG, et al. Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes-the EURODIAB Prospective Complications Study. Diabetologia 2005; 48: 370-378.
29. Gillespie KM, Bain SC, Barnett AH, et al. The rising incidence of childhood type 1 diabetes and reduced contribution of high-risk HLA haplotypes. Lancet 2004; 364: 1699-1700.
30. Hermann R, Knip M, Veijola R, et al. Temporal changes in the frequencies of HLA genotypes in patients with Type 1 diabetes-indication of an increased environmental pressure? Diabetologia 2003; 46: 420-425.
31. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 2003; 46: 3-19.
32. Kolb H, Mandrup-Poulsen T. An immune origin of type 2 diabetes? Diabetologia 2005; 48: 1038-1050.
33. Pietropaolo M, Barinas-Mitchell E, Pietropaolo SL, et al. Evidence of islet cell autoimmunity in elderly patients with type 2 diabetes. Diabetes 2000; 49: 32-38.
34. Pittoni V, Valesini G. The clearance of apoptotic cells: implications for autoimmunity. Autoimmun Rev 2002; 1: 154-161.
35. Zimmet PZ, Tuomi T, Mackay IR, et al. Latent autoimmune diabetes mellitus in adults (LADA): the role of antibodies to glutamic acid decarboxylase in diagnosis and prediction of insulin dependency. Diabet Med 1994; 11: 299-303.
36. Zimmet P, Turner R, McCarty D, et al. Crucial points at diagnosis. Type 2 diabetes or slow type 1 diabetes. Diabetes Care 1999; 22(Suppl. 2): B59-B64.
37. Carlsson A, Sundkvist G, Groop L, et al. Insulin and glucagon secretion in patients with slowly progressing autoimmune diabetes (LADA). J Clin Endocrinol Metab 2000; 85: 76-80.
38. Terhorst C, van AA, LeClair K, et al. Biochemical studies of the human thymocyte cell-surface antigens T6, T9 and T1O. Cell 1981; 23: 771-780.
39. Jackson DG, Bell JI. Isolation of a cDNA encoding the human CD38 (T10) molecule, a cell surface glycoprotein with an unusual discontinuous pattern of expression during lymphocyte differentiation. J Immunol 1990; 144: 2811-2815.
40. Mallone R, Funaro A, Zubiaur M, et al. Signaling through CD38 induces NK cell activation. Int Immunol 2001; 13: 397-409.
41. Zocchi E, Franco L, Guida L, et al. A single protein immunologically identified as CD38 displays NAD+ glycohydrolase, ADP-ribosyl cyclase and cyclic ADP-ribose hydrolase activities at the outer surface of human erythrocytes. Biochem Biophys Res Commun 1993; 196: 1459-1465.
42. Ramaschi G, Torti M, Festetics ET, et al. Expression of cyclic ADP-ribose-synthetizing CD38 molecule on human platelet membrane. Blood 1996; 87: 2308-2313.
43. Zupo S, Rugari E, Dono M, et al. CD38 signaling by agonistic monoclonal antibody prevents apoptosis of human germinal center B cells. Eur J Immunol 1994; 24: 1218-1222.
44. Kumagai M, Coustan-Smith E, Murray DJ, et al. Ligation of CD38 suppresses human B lymphopoiesis. J Exp Med 1995; 181: 1101-1110.
45. Deaglio S, Mallone R, Baj G, et al. Human CD38 and its ligand CD31 define a unique lamina propria T lymphocyte signaling pathway. FASEB J 2001; 15: 580-582.
46. Fernandez JE, Deaglio S, Donati D, et al. Analysis of the distribution of human CD38 and of its ligand CD31 in normal tissues. J Biol Regul Homeost Agents 1998; 12: 81-91.
47. Mallone R, Ortolan E, Pinach S, et al. Anti-CD38 autoantibodies: characterisation in new-onset type I diabetes and latent autoimmune diabetes of the adult (LADA) and comparison with other islet autoantibodies. Diabetologia 2002; 45: 1667-1677.
48. Nata K, Takamura T, Karasawa T, et al. Human gene encoding CD38 (ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase): organization, nucleotide sequence and alternative splicing. Gene 1997; 186: 285-292.
49. Mallone R, Ferrua S, Morra M, et al. Characterization of a CD38-like 78-kilodalton soluble protein released from B cell lines derived from patients with X-linked agammaglobulinemia. J Clin Invest 1998; 101: 2821-2830.
50. Umar S, Malavasi F, Mehta K. Post-translational modification of CD38 protein into a high molecular weight form alters its catalytic properties. J Biol Chem 1996; 271: 15922-15927.
51. Anderton SM. Post-translational modifications of self antigens: implications for autoimmunity. Curr Opin Immunol 2004; 16: 753-758.
52. Malavasi F, Funaro A, Roggero S, et al. Human CD38: a glycoprotein in search of a function. Immunol Today 1994; 15: 95-97.
53. Ferrero E, Malavasi F. The metamorphosis of a molecule: from soluble enzyme to the leukocyte receptor CD38. J Leukoc Biol 1999; 65: 151-161.
54. Deaglio S, Mallone R, Baj G, et al. CD38/CD31, a receptor/ligand system ruling adhesion and signaling in human leukocytes. Chem Immunol 2000; 75: 99-120.
55. Deaglio S, Morra M, Mallone R, et al. Human CD38 (ADP-ribosyl cyclase) is a counter-receptor of CD31, an Ig superfamily member. J Immunol 1998; 160: 395-402.
56. Ausiello CM, la SA, Ramoni C, et al. Secretion of IFN-gamma, IL-6, granulocyte-macrophage colony-stimulating factor and IL-10 cytokines after activation of human purified T lymphocytes upon CD38 ligation. Cell Immunol 1996; 173: 192-197.
57. Howard M, Grimaldi JC, Bazan JF, et al. Formation and hydrolysis of cyclic ADP-ribose catalyzed by lymphocyte antigen CD38. Science 1993; 262: 1056-1059.
58. Berridge MJ. Cell signalling. A tale of two messengers. Nature 1993; 365: 388-389.
59. Galione A. Cyclic ADP-ribose: a new way to control calcium. Science 1993; 259: 325-326.
60. Takasawa S, Nata K, Yonekura H, et al. Cyclic ADP-ribose in insulin secretion from pancreatic beta cells. Science 1993; 259: 370-373.
61. Kato I, Takasawa. S, Akabane A, et al. Regulatory role of CD38 (ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase) in insulin secretion by glucose in pancreatic beta cells. Enhanced insulin secretion in CD38-expressing transgenic mice. J Biol Chem 1995; 270: 30045-30050.
62. Kato I, Yamamoto Y, Fujimura M, et al. CD38 disruption impairs glucose-induced increases in cyclic ADP-ribose, [Ca2+]i, and insulin secretion. J Biol Chem 1999, 274: 1869-1872.
63. Okamoto H, Takasawa S, Nata K. The CD38-cyclic ADP-ribose signalling system in insulin secretion: molecular basis and clinical implications. Diabetologia 1997; 40: 1485-1491.
64. Ashcroft FM, Harrison DE, Ashcroft SJ. Glucose induces closure of single potassium channels in isolated rat pancreatic beta-cells. Nature 1984; 312: 446-448.
65. Takasawa S, Tohgo A, Noguchi N, et al. Synthesis and hydrolysis of cyclic ADP-ribose by human leukocyte antigen CD38 and inhibition of the hydrolysis by ATP. J Biol Chem 1993; 268: 26052-26054.
66. Ikehata F, Satoh J, Nata K, et al. Autoantibodies against CD38 (ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase) that impair glucose-induced insulin secretion in noninsulin- dependent diabetes patients. J Clin Invest 1998; 102: 395-401.
67. Pupilli C, Giannini S, Marchetti P, et al. Autoantibodies to CD38 (ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase) in Caucasian patients with diabetes: effects on insulin release from human islets. Diabetes 1999; 48: 2309-2315.
68. Munshi CB, Fryxell KB, Lee HC, et al. Large-scale production of human CD38 in yeast by fermentation. Meth Enzymol 1997; 280: 318-330.
69. Mallone R, Ortolan E, Baj G, et al. Autoantibody response to CD38 in Caucasian patients with type 1 and type 2 diabetes: immunological and genetic characterization. Diabetes 2001; 50: 752-762.
70. Antonelli A, Baj G, Marchetti P, et al. Human anti-CD38 autoantibodies raise intracellular calcium and stimulate insulin release in human pancreatic islets. Diabetes 2001; 50: 985-991.
71. Savola K, Sabbah E, Kulmala P, et al. Autoantibodies associated with Type I diabetes mellitus persist after diagnosis in children. Diabetologia 1998; 41: 1293-1297.
72. Antonelli A, Fallahi P, Nesti C, et al. Anti-CD38 autoimmunity in patients with chronic autoimmune thyroiditis or Graves' disease. Clin Exp Immunol 2001; 126: 426-431.
73. Kawasaki E, Abiru N, Yano M, et al. Autoantibodies to glutamic acid decarboxylase in patients with autoimmune thyroid disease: relation to competitive insulin autoantibodies. J Autoimmun 1995; 8: 633-643.
74. Hallengren B, Falorni A, Landin-Olsson M, et al. Islet cell and glutamic acid decarboxylase antibodies in hyperthyroid patients: at diagnosis and following treatment. J Intern Med 1996; 239: 63-68.
75. Maugendre D, Verite F, Guilhem I, et al. Anti-pancreatic autoimmunity and Graves' disease: study of a cohort of 600 Caucasian patients. Eur J Endocrinol 1997; 137: 503-510.
76. Martin S, Wolf-Eichbaum D, Duinkerken G, et al. Development of type 1 diabetes despite severe hereditary B-lymphocyte deficiency. N Engl J Med 2001; 345: 1036-1040.
77. Reijonen H, Daniels TL, Lernmark A, et al. GAD65-specific autoantibodies enhance the presentation of an immunodominant T-cell epitope from GAD65. Diabetes 2000; 49: 1621-1626.
78. Jaume JC, Parry SL, Madec AM, et al. Suppressive effect of glutamic acid decarboxylase 65-specific autoimmune B lymphocytes on processing of T cell determinants located within the antibody epitope. J Immunol 2002; 169: 665-672.
79. Grill V, Bjorklund A. Overstimulation and beta-cell function. Diabetes 2001; 50(Suppl. 1): S122-S124.
80. Chandra J, Zhivotovsky B, Zaitsev S, et al. Role of apoptosis in pancreatic beta-cell death in diabetes. Diabetes 2001; 50(Suppl. 1): S44-S47.
81. Marchetti P, Antonelli A, Lupi R, et al. Prolonged in vitro exposure to autoantibodies against CD38 impairs the function and survival of human pancreatic islets. Diabetes 2002; 51(Suppl. 3): S474-S477.
82. Lanzavecchia A. How can cryptic epitopes trigger autoimmunity? J Exp Med 1995; 181: 1945-1948.
83. Simitsek PD, Campbell DG, Lanzavecchia A, et al. Modulation of antigen processing by bound antibodies can boost or suppress class II major histocompatibility complex presentation of different T cell determinants. J Exp Med 1995; 181: 1957-1963.